AustriaAustria

Mutations in mtRNA associated with increased PSA and prostate cancer

03.12.2010

Innsbruck – Austrian researchers have uncovered mutations throughout the mitochondrial genome that are associated with prostate cancer (Am. J. Human Genetics, 2 December). mtRNA mutations identified by a team headed by Dr. Anita Kloss-Brandstätter from Innsbruck Medical University, were found to be associated with elevated levels of prostate-specific antigen (PSA) in Austrian men diagnosed with various stages of prostate cancer. The group used a high-quality sequencing approach to detect differences in mtDNA sequence between cancerous and noncancerous tissue from the same 30 men."It is the first study targeting the entire mitochondrial genome in prostate cancer and benign tissue from the same patient with a superior sequencing strategy,"notes Dr. Kloss-Brandstätter By examining both the frequency and types of somatic mtDNA mutations in prostate cancer patients, Dr. Kloss-Brandstätter and colleagues were able to identify several genetic changes having clinical significance. They suggest that,"sequencing of selected mitochondrial regions will likely result in a mutation spectrum useful for prognosis."Perhaps the most striking finding of the study is the association between somatic mtRNA mutations and PSA levels at diagnosis. "Patients with a somatic tRNA mutation had a significantly higher PSA value at diagnosis than did patients without a somatic mtRNA mutation," explains Dr. Kloss-Brandstätter."These findings will potentially help others monitor malignant transformation, tumor progression, and metastasis,"she says.

AustriaAustria

04.06.2009

Vienna – Glycobiology specialist Prot­Affin AG has announced the completion of a EUR14.1m second round, co-led by Atlas Venture and SR One Ltd, the corporate venture fund of GlaxoSmithKline. Existing investors Aescap Venture,...

AustriaAustria

29.04.2009

Vienna – Intercell AG has received good news from the American Food and Drug Administration; its Japanese encephalitis vaccine Ixiaro® has now been approved in the US. That gives Intercell the chance to strike an important deal...

AustriaAustria

21.02.2009

Vienna/New York – Feeling safe activates cellular and molecular processes that act against depression (Neuron 60(1):149-61). A new animal model that helps examine and explain the relevant cell biology processes shows that...

AustriaAustria

21.02.2009

Vienna – Austria’s scientific community is worried about a cut in national research support due to the worldwide financial crisis. Last year, a105m were channeled to research in Austria through the “Jubiläumsfonds”, a foundation...

AustriaAustria

21.02.2009

Vienna – Austria’s scientific community is worried about a cut in national research support due to the worldwide financial crisis. Last year, a105m were channeled to research in Austria through the “Jubiläumsfonds”, a foundation...

AustriaAustria

20.02.2009

Austrian vaccine developer Intercell AG (Vienna) announced in January that it has initiated a Phase II clinical study to test IC43, a vaccine candidate to prevent opportunistic infections with Pseudomonas aeruginosa. The...

AustriaAustria

03.10.2008

Innsbruck – A heated debate on scientific misconduct in Austria has reached fresh heights after the Medical University of Innsbruck fired rector Clemens Sorg due to “severe breach of duty”. In a private letter to colleagues and...

AustriaAustria

14.08.2008

Graz – Austria-based metabolomics company Biocrates AG has entered into a worldwide co-marketing agreement with Applied Biosystems, the world leader in mass spectrometry to be overtaken by Invitrogen. Under the terms of the...

AustriaAustria

14.08.2008

Vienna – Intercell AG has acquired US vaccine developer Iomai after it posted some impressive data on both a new therapy for traveler’s diarrhea and an adjuvant for bird flu vaccines. The Austrian biotech has paid $189m for the...

Displaying results 41 to 50 out of 116

< Previous 41-50 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/4/article/mutations-in-mtrna-associated-with-increased-psa-and-prostate-cancer.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)305.50 GBP39.3%
  • NEWRON (CH)15.60 CHF20.0%
  • TOPOTARGET (DK)3.52 DKK16.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • WILEX (D)0.84 EUR-8.7%
  • GENFIT (F)22.42 EUR-8.1%

TOP

  • BIOTECH PHARMACON (N)18.80 NOK71.7%
  • WILEX (D)0.84 EUR47.4%
  • E-THERAPEUTICS (UK)27.75 GBP38.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.3%
  • IMMUNICUM AB (S)16.60 SEK-36.2%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6265.9%
  • IXICO (UK)68.00 GBP756.4%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper